EUVIMEDDescobrir EUVIMED
Crossref

Anlotinib induces neuronal‐like differentiation of neuroblastoma by downregulating CRMP5

Junwen Hu, Wenlong Yang, Kang Wang, Hongyan Xu, Tianxiang Chen, Chao Li, Ting Xiong, Han Xu, Ming Luo, Shouhua Zhang iD, Jinlong Yan

Molecular Carcinogenesis · 2024

DOI: 10.1002/mc.23745 ↗

At a glance

Journal article in Molecular Carcinogenesis, 2024. Written by Junwen Hu and 10 co-authors. Institution: Department of General Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China. Major MEDLINE topics: Neuroblastoma, Quinolines, Cell Differentiation, Xenograft Model Antitumor Assays. 24 references. Funded by: Science and Technology Program of Jiangxi Administration of Traditional Chinese Medicine, Jiangxi Provincial Health Technology Project, Science Technology Foundation of Jiangxi Province.

ResumoSubjectsDados bibliográficosCiteRelated studies

Abstract (original language)

The therapeutic effect of anlotinib on neuroblastoma is still not fully understood. This study aims to explore the differentiation therapeutic effects of anlotinib on neuroblastoma and its potential association with the neural development regulatory protein collapsin response mediator protein 5 (CRMP5), both in vivo and in vitro. A patient‐derived xenograft (PDX) model was established to observe the therapeutic effect of anlotinib. Neuroblastoma cell lines SK‐N‐SH and SK‐N‐AS were cultured to observe the morphological impact of anlotinib. Transwell assay was used to evaluate the cell invasion, and Western blot analysis and immunohistochemistry were employed to detect the expressions of neuronal differentiation‐related proteins. Results indicate that anlotinib effectively inhibited tumor growth in the PDX model, modulated the expressions of neuronal differentiation markers. In vitro, anlotinib treatment induced neurite outgrowth in neuroblastoma cells and inhibited their invasive ability, reflecting a change in neuronal marker expression patterns consistent with the PDX model. Similarly, in the SK‐N‐AS mouse xenograft model, anlotinib demonstrated comparable tumor‐suppressing effects and promoted neuronal‐like differentiation. Additionally, anlotinib significantly downregulated CRMP5 expression in neuroblastoma both in vivo and in vitro. Overexpression of CRMP5 significantly reversed the differentiation therapy effect of anlotinib, exacerbating the aggressiveness and reducing the differentiation level of neuroblastoma. These findings highlight the potential of anlotinib as an anti‐neuroblastoma agent. It may suppress tumor proliferation and invasion by promoting the differentiation of tumor cells towards a neuronal‐like state, and this differentiation therapy effect involves the inhibition of CRMP5 signaling.

Subjects

MeSH terms (MEDLINE)

NeuroblastomaQuinolinesCell DifferentiationXenograft Model Antitumor AssaysIndolesNerve Tissue ProteinsCell ProliferationHumansAnimalsMiceCell Line, TumorGene Expression Regulation, NeoplasticDown-RegulationNeuronsMice, NudeHydrolasesAntineoplastic AgentsMicrotubule-Associated Proteins

Author keywords

CRMP5anlotinibdifferentiation therapyneuroblastoma

Substances

QuinolinesanlotinibIndolesNerve Tissue ProteinsDPYSL5 protein, humanHydrolasesAntineoplastic AgentsMicrotubule-Associated Proteins

Authors and institutions

  • Department of General Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
  • Department of Infectious Diseases, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
  • Department of Traditional Chinese Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
  • Department of General Surgery, The Affiliated Children's Hospital of Nanchang Medical College, Nangchang, China.
  • Department of General Surgery, Jiangxi Provincial Children's Hospital, Nanchang, Jiangxi, China.

ORCID profiles: Shouhua Zhang

Funding

  • Science and Technology Program of Jiangxi Administration of Traditional Chinese Medicine
  • Jiangxi Provincial Health Technology Project
  • Science Technology Foundation of Jiangxi Province
  • National Natural Science Foundation of China

Cite

APA

Hu, J., Yang, W., Wang, K., Xu, H., Chen, T., Li, C., Xiong, T., Xu, H., Luo, M., Zhang, S., & Yan, J. (2024). Anlotinib induces neuronal‐like differentiation of neuroblastoma by downregulating CRMP5. Molecular Carcinogenesis. https://doi.org/10.1002/mc.23745

Vancouver

Hu J, Yang W, Wang K, Xu H, Chen T, Li C, et al. Anlotinib induces neuronal‐like differentiation of neuroblastoma by downregulating CRMP5. Molecular Carcinogenesis. 2024. doi:10.1002/mc.23745

BibTeX
@article{Hu2024,
  author = {Hu, Junwen and Yang, Wenlong and Wang, Kang and Xu, Hongyan and Chen, Tianxiang and Li, Chao and Xiong, Ting and Xu, Han and Luo, Ming and Zhang, Shouhua and Yan, Jinlong},
  title = {Anlotinib induces neuronal‐like differentiation of neuroblastoma by downregulating CRMP5},
  journal = {Molecular Carcinogenesis},
  year = {2024},
  doi = {10.1002/mc.23745}
}
Start for free →